#United States #Orlando #Candela #Vbeam Pro #Laser Treatment

A New Era in Laser Technology: Candela's Vbeam Pro

In an exciting development for the field of medical aesthetics, Candela Corporation has officially launched its groundbreaking Vbeam Pro® laser platform. This innovative device was unveiled during the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS), showcasing a significant leap in the realm of vascular and dermatologic treatment options.

The Evolution of Laser Treatments

Candela has long been a leader in energy-based medical aesthetics, leveraging over four decades of clinical expertise in pulsed dye laser (PDL) technology. The Vbeam Pro now sets a new benchmark for the treatment of various skin conditions. The device is distinguished by its combination of a 595 nm pulsed dye laser and a 1064 nm NdYAG wavelength, offering an unprecedented level of precision and versatility for clinicians.

Not only is the Vbeam Pro the first vascular laser cleared by the FDA for pediatric applications, but it also accommodates a wide range of skin conditions. With its capabilities, practitioners can effectively target issues such as rosacea, acne, leg and spider veins, scars, benign pigmented lesions, and signs of photoaging, making it a versatile tool in dermatologic care.

Enhanced Efficacy and Patient Outcomes

According to Dr. Roy Geronemus, Clinical Professor at NYU Grossman School of Medicine and Medical Director of the Vascular Birthmarks Foundation, “The Vbeam Pro system is a transformative evolution in pulsed dye laser technology. Patients are experiencing remarkable outcomes compared to earlier systems.” This was further confirmed by rigorous clinical research that shows the device achieves:
20% improved clearance of treated lesions compared to its predecessors.
50% faster treatment times, allowing for more efficient patient management.
* 20% reduction in reported patient discomfort, enhancing the overall treatment experience.

The Vbeam Pro combines state-of-the-art energy delivery control, refining the treatment process with 30% tighter energy delivery. This precision not only elevates the treatment efficacy but also ensures safer outcomes for all Fitzpatrick skin types, ranging from I to VI.

Commitment to Clinical Rigor

Candela’s dedication to quality and patient safety is evident in the extensive clinical evaluations carried out with leading dermatology practices across the United States. “We put the platform through stringent testing in busy clinical environments, yielding feedback that underscores its potential in improving patient outcomes,” stated Dr. Konika Patel Schallen, Senior Vice President of Clinical Operations at Candela. This commitment to evidence-based practice reflects Candela's ethos of rigor and reliability in its medical devices.

A Major Leap Forward

Geoffrey Crouse, CEO of Candela, expressed that the launch of the Vbeam Pro underscores the company’s commitment to continuous innovation rooted in science and trusted partnerships with healthcare providers. He noted, “Building on our longstanding clinical leadership, the introduction of the Vbeam Pro system represents a major leap forward in treating vascular and other skin conditions.”

As the company prepares to showcase the Vbeam Pro at ASLMS 2025, attendees are encouraged to visit Candela’s booth to experience the platform firsthand. For more information, visit candelamedical.com.

The Vbeam Pro is set to redefine standards in dermatologic treatment and opens new horizons for clinicians and patients alike, paving the way for superior care and results in medical aesthetics.

• ---